NOX Pipeline Boosted by $1.5M Grant to Hudson Institute
Filed with ASX · · 3 pages · English
Story so far
Earlier from Noxopharm
- September 2022 Quarterly Activities Report and Appendix 4C
- Novel Dual-cell Therapy Results in Pancreatic Cancer
- Response to ASX Price Query
- June 2022 Quarterly Activities Report and Appendix 4C
- March 2022 Quarterly Activities Report and Appendix 4C
Later from Noxopharm
- DARRT-2 Trial Efficacy Phase to Commence
- December 2022 Quarterly Activities Report and Appendix 4C
- Appendix 4D and Half Year 2023 Financial Report
- Noxopharm Announces Novel mRNA Vaccine Enhancer
- Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm